Short-term and long-term efficacy and safety evaluation of acupoint catgut embedding in the simple obesity: a randomized controlled double-blind trial

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046693

Enrollment

Unknown

Registered

2021-05-26

Start date

2021-06-01

Completion date

Unknown

Last updated

2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

simple obesity

Interventions

Experimental group1:acupoint catgut embedding

Experimental group2:Needle the same but do not implant the line body

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Meet the diagnostic criteria for being overweight or obese; 2.Aged 18 to 60 years; 3.Have not received any other weight-loss treatment within the last 3 months; 4.Volunteered to participate in the study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1.Allergic to alcohol or PGLA; 2.Pregnant or lactation patients; 3.Secondary obesity, as follows thalamus, pituitary disease, hypothyroidism, increased cortisol, increased insulin, changes in gonadal secretion and drugs caused by secondary obesity patients; 4.Complicated with serious cardiovascular and cerebrovascular diseases, liver and kidney diseases, mental or emotional disorders unable to cooperate;Local skin damage or infection; 5.Patients with abnormal coagulation function.

Design outcomes

Primary

Measure	Time frame
clinical efficacy;	—

Secondary

Measure	Time frame
safety evaluation;	—

Countries

China

Contacts

Public ContactYang Qiwang

The Fifth Affiliated Hospital of Southern Medical University

yangqiwang19@163.com+86 13824421646

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026